Fabienne Orsi

Personal Details

First Name:	Fabienne
Middle Name:
Last Name:	Orsi
Suffix:
RePEc Short-ID:	por87
	[This author has chosen not to make the email address public]

Affiliation

Institut de Recherche pour le Développement (IRD)

Montpellier, France
http://www.france-sud.ird.fr/
RePEc:edi:irdmpfr (more details at EDIRC)

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Articles

1. Benjamin Coriat & Fabienne Orsi & Cristina d'Almeida, 2006. "TRIPS and the international public health controversies: issues and challenges," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 15(6), pages 1033-1062, December.

   Cited by:

   1. Jean-Paul Moatti & Bruno Ventelou, 2009. "Économie de la santé dans les pays en développement des paradigmes en mutation," Revue économique, Presses de Sciences-Po, vol. 60(2), pages 241-256.
   2. Francesco Laforgia & Fabio Montobbio & Luigi Orsenigo, 2007. "IPRs, technological and industrial development and growth: the case of the pharmaceutical industry," KITeS Working Papers 206, KITeS, Centre for Knowledge, Internationalization and Technology Studies, Universita' Bocconi, Milano, Italy, revised Oct 2007.
   3. F. Montobbio & A. Primi & Valerio Sterzi, 2015. "IPRs and international knowledge flows: Evidence from six large emerging countries," Post-Print hal-02486325, HAL.
      • Fabio Montobbio & Annalisa Primi & Valerio Sterzi, 2015. "IPRs and International Knowledge Flows: Evidence from Six Large Emerging Countries," Tijdschrift voor Economische en Sociale Geografie, Royal Dutch Geographical Society KNAG, vol. 106(2), pages 187-204, April.
   4. Giovanni Dosi, 2021. "Some policy lessons from medical/therapeutic responses to the COVID-19 Crisis: A rich research system for knowledge generation and dysfunctional institutions for its exploitation," LEM Papers Series 2021/19, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
   5. Fabienne Orsi & Jean-Benoît Zimmermann, 2011. "Propriété intellectuelle et globalisation: des TRIPS au modèle open-source. Les exemples des médicaments et du logiciel," Working Papers halshs-00561477, HAL.
      • Fabienne Orsi & Jean-Benoît Zimmermann, 2013. "Propriété intellectuelle et globalisation: des TRIPS au modèle open-source. Les exemples des médicaments et du logiciel," Post-Print hal-01500884, HAL.
   6. Fabio MONTOBBIO & Valerio STERZI, 2012. "The globalization of technology in emerging markets: a gravity model on the determinants of international patent collaborations," Cahiers du GREThA (2007-2019) 2012-05, Groupe de Recherche en Economie Théorique et Appliquée (GREThA).
      • Fabio Montobbio & Valerio Sterzi, 2012. "The globalization of technology in emerging markets: a gravity model on the determinants of international patent collaborations," Post-Print hal-00779900, HAL.
      • Montobbio, Fabio & Sterzi, Valerio, 2013. "The Globalization of Technology in Emerging Markets: A Gravity Model on the Determinants of International Patent Collaborations," World Development, Elsevier, vol. 44(C), pages 281-299.
      • Montobbio Fabio & Sterzi Valerio, 2012. "The globalization of technology in emerging markets: a gravity model on the determinants of international patent collaborations," Department of Economics and Statistics Cognetti de Martiis LEI & BRICK - Laboratory of Economics of Innovation "Franco Momigliano", Bureau of Research in Innovation, Complexity and Knowledge, Collegio 201208, University of Turin.
   7. Giovanni Dosi, 2021. "Policy Lessons From Medical Responses to the COVID-19 Crisis," Intereconomics: Review of European Economic Policy, Springer;ZBW - Leibniz Information Centre for Economics;Centre for European Policy Studies (CEPS), vol. 56(6), pages 337-340, November.
   8. Beniamino Callegari & Christophe Feder, 2022. "The long-term economic effects of pandemics: toward an evolutionary approach [Epidemics and trust: the case of the Spanish flu]," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 31(3), pages 715-735.
   9. Benjamin Coriat & Fabienne Orsi & Jean Francois Alessandrini & Pascale Boulet & Sauman Singh-Phulgenda, 2023. "Health and access to care : why it is necessary and urgent to switch from a global public good approach to a commons based approach," LEM Papers Series 2023/08, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
   10. Pallab Paul & Kausiki Mukhopadhyay, 2010. "Growth via Intellectual Property Rights Versus Gendered Inequity in Emerging Economies: An Ethical Dilemma for International Business," Journal of Business Ethics, Springer, vol. 91(3), pages 359-378, February.
   11. Abecassis, Philippe & Coutinet, Nathalie, 2015. "Médicaments génériques : pivot de la reconstruction de l’industrie pharmaceutique," Revue de la Régulation - Capitalisme, institutions, pouvoirs, Association Recherche et Régulation, vol. 17.
   12. Giovanni Dosi & Joseph Stiglitz, 2013. "The Role of Intellectual Property Rights in the Development Process, with Some Lessons from Developed Countries: An Introduction," LEM Papers Series 2013/23, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.

2. Fabienne Orsi & Benjamin Coriat, 2005. "Are "strong patents" beneficial to innovative activities? Lessons from the genetic testing for breast cancer controversies," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 14(6), pages 1205-1221, December.

   Cited by:

   1. Elizabeth Webster & Paul H. Jensen, 2009. "Do Patents Matter for Commercialization?," Melbourne Institute Working Paper Series wp2009n08, Melbourne Institute of Applied Economic and Social Research, The University of Melbourne.
      • Elizabeth Webster & Paul H. Jensen, 2011. "Do Patents Matter for Commercialization?," Journal of Law and Economics, University of Chicago Press, vol. 54(2), pages 431-453.

3. Michael Hoy & Fabienne Orsi & François Eisinger & Jean Paul Moatti, 2003. "The Impact of Genetic Testing on Healthcare Insurance," The Geneva Papers on Risk and Insurance - Issues and Practice, Palgrave Macmillan;The Geneva Association, vol. 28(2), pages 203-221, April.

   Cited by:

   1. Bardey, David & De Donder, Philippe, 2019. "A Welfare Analysis of Genetic Testing in Health Insurance Markets with Adverse Selection and Prevention," TSE Working Papers 19-1035, Toulouse School of Economics (TSE), revised 22 Jan 2024.
      • David Bardey & Philippe de Donder, 2024. "A Welfare Analysis of Genetic Testing in Health Insurance Markets with Adverse Selection and Prevention," Working Papers hal-04082748, HAL.
   2. M. Martin Boyer & Franca Glenzer, 2021. "Pensions, annuities, and long-term care insurance: on the impact of risk screening," The Geneva Risk and Insurance Review, Palgrave Macmillan;International Association for the Study of Insurance Economics (The Geneva Association), vol. 46(2), pages 133-174, September.
   3. Oster, Emily & Shoulson, Ira & Quaid, Kimberly & Dorsey, E. Ray, 2010. "Genetic adverse selection: Evidence from long-term care insurance and Huntington disease," Journal of Public Economics, Elsevier, vol. 94(11-12), pages 1041-1050, December.
      • Emily Oster & Ira Shoulson & Kimberly Quaid & E. Ray Dorsey, 2009. "Genetic Adverse Selection: Evidence from Long-Term Care Insurance and Huntington Disease," NBER Working Papers 15326, National Bureau of Economic Research, Inc.
   4. Winand Emons, 2006. "Genetic Tests and Intertemporal Screening in Competitive Insurance Markets," Diskussionsschriften dp0605, Universitaet Bern, Departement Volkswirtschaft.
      • Emons Winand, 2009. "Genetic Tests and Inter-Temporal Screening in Competitive Insurance Markets," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 9(1), pages 1-19, July.
      • Emons, Winand, 2007. "Genetic Tests and Intertemporal Screening in Competitive Insurance Markets," CEPR Discussion Papers 6047, C.E.P.R. Discussion Papers.
   5. Mimra, Wanda & Nemitz, Janina & Waibel, Christian, 2020. "Voluntary pooling of genetic risk: A health insurance experiment," Journal of Economic Behavior & Organization, Elsevier, vol. 180(C), pages 864-882.
   6. Stefano Bosi & Claire Rogel Gaillard, 2018. "Biologie prédictive pour la santé. Regards croisés sur les enjeux socio-économiques et scientifiques chez l'Homme, les animaux et les plantes," Post-Print hal-02786221, HAL.
   7. David Bardey & Philippe De Donder & César Mantilla, 2014. "Adverse Selection vs Discrimination Risk with Genetic Testing. An Experimental Approach," Documentos CEDE 12341, Universidad de los Andes, Facultad de Economía, CEDE.
      • David Bardey & Philippe De Donder & Cesar Mantilla, 2014. "Adverse Selection vs Discrimination Risk with Genetic Testing. An Experimental Approach," CESifo Working Paper Series 5080, CESifo.
   8. Michael Hoy & Michael Ruse, 2005. "Regulating Genetic Information in Insurance Markets," Risk Management and Insurance Review, American Risk and Insurance Association, vol. 8(2), pages 211-237, September.
   9. David Bardey & Philippe De Donder & César Mantilla, 2017. "How Is the Trade-off between Adverse Selection and Discrimination Risk Affected by Genetic Testing? Theory and Experiment," Documentos CEDE 15465, Universidad de los Andes, Facultad de Economía, CEDE.
      • Bardey, David & De Donder, Philippe & Mantilla, César, 2019. "How is the trade-off between adverse selection and discrimination risk affected by genetic testing? Theory and experiment," Journal of Health Economics, Elsevier, vol. 68(C).
      • Bardey, David & De Donder, Philippe & Mantilla, Cesar, 2017. "How Is the Trade-off between Adverse Selection and Discrimination Risk Affected by Genetic Testing?: Theory and Experiment," TSE Working Papers 17-777, Toulouse School of Economics (TSE), revised Jul 2019.
      • David Bardey & Philippe De Donder & Cesar Mantilla, 2017. "How is the Trade-off between Adverse Selection and Discrimination Risk Affected by Genetic Testing? Theory and Experiment," CESifo Working Paper Series 6402, CESifo.
   10. Vicky Barham & Rose Anne Devlin & Olga Milliken, 2016. "Genetic Health Risks: The Case for Universal Public Health Insurance," Working Papers 1605E, University of Ottawa, Department of Economics.
   11. David Bardey & Philippe De Donder, 2015. "Welfare Impacts of Genetic Testing in Health Insurance Markets: Will Cross-Subsidies Survive?," Documentos CEDE 17220, Universidad de los Andes, Facultad de Economía, CEDE.
   12. Christine Arentz, 2012. "Auswirkungen von Gentests in der Krankenversicherung," Otto-Wolff-Institut Discussion Paper Series 04/2012, Otto-Wolff-Institut für Wirtschaftsordnung, Köln, Deutschland.
   13. Hoel, Michael & Iversen, Tor & Nilssen, Tore & Vislie, Jon, 2006. "Genetic testing in competitive insurance markets with repulsion from chance: A welfare analysis," Journal of Health Economics, Elsevier, vol. 25(5), pages 847-860, September.
   14. David Crainich, 2017. "Self-Insurance With Genetic Testing Tools," Journal of Risk & Insurance, The American Risk and Insurance Association, vol. 84(1), pages 73-94, March.
       • David Crainich, 2015. "Self-Insurance With Genetic Testing Tools," Post-Print hal-01533549, HAL.
   15. Wanda Mimra & Janina Nemitz & Christian Waibel, 2019. "Voluntary pooling of genetic risk: A health insurance experiment," Post-Print hal-02499086, HAL.
   16. Ray Rees & Patricia Apps, 2006. "Genetic testing, income distribution and insurance markets, CHERE Working Paper 2006/3," Working Papers 2006/3, CHERE, University of Technology, Sydney.
   17. Michael Hoy & Michael Ruse, 2008. "“No Solution to This Dilemma Exists”: Discrimination, Insurance, and the Human Genome Project," Working Papers 0808, University of Guelph, Department of Economics and Finance.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Fabienne Orsi should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.